Scholarlink

<p>Diagnosis of stage 1 breast cancer is challenging as small tumors are often left undetected by conventional imaging techniques. In addition, ~80% of detected breast masses are classified as benign, which means that a large proportion of diagnostic needle biopsies lead to unnecessary psychological stress and medical costs. We investigated circulating extracellular vesicles (EVs) as potential carriers of unique cancer-associated proteins capable of reporting on a breast cancer diagnosis. We isolated EVs from healthy (19), benign (19), and stage 1 breast cancer patient (86) plasma samples using size exclusion chromatography. Mass spectrometry identified 94 significantly changed proteins in the plasma EVs from breast cancer patients. Analysis of a subset of these proteins using a cohort of pre- and post-operative breast cancer patient plasma EVs identified enolase 1 as a promising biomarker. We further validated enolase 1 in a larger patient cohort by high-throughput ELISA of plasma. Enolase 1 was found to be significantly elevated in plasma from stage 1 breast cancer patients compared to healthy and benign individuals, and decreased in post-operative plasma upon tumor removal. Our findings suggest that an enolase 1 liquid blood biopsy could be used to support the detection of breast cancer at the earliest, most treatable, stage.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Circulating enolase 1 as a diagnostic biomarker for early-stage breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月17日

查看全文
  • Nikki Salmond,
  • Renata Moravcova,
  • Wing Sum Tam,
  • Karan Khanna,
  • Jason C. Rogalski,
  • Kalan Lynn,
  • Muriel Brackstone,
  • Peter H. Watson,
  • Karla C. Williams

摘要

Diagnosis of stage 1 breast cancer is challenging as small tumors are often left undetected by conventional imaging techniques. In addition, ~80% of detected breast masses are classified as benign, which means that a large proportion of diagnostic needle biopsies lead to unnecessary psychological stress and medical costs. We investigated circulating extracellular vesicles (EVs) as potential carriers of unique cancer-associated proteins capable of reporting on a breast cancer diagnosis. We isolated EVs from healthy (19), benign (19), and stage 1 breast cancer patient (86) plasma samples using size exclusion chromatography. Mass spectrometry identified 94 significantly changed proteins in the plasma EVs from breast cancer patients. Analysis of a subset of these proteins using a cohort of pre- and post-operative breast cancer patient plasma EVs identified enolase 1 as a promising biomarker. We further validated enolase 1 in a larger patient cohort by high-throughput ELISA of plasma. Enolase 1 was found to be significantly elevated in plasma from stage 1 breast cancer patients compared to healthy and benign individuals, and decreased in post-operative plasma upon tumor removal. Our findings suggest that an enolase 1 liquid blood biopsy could be used to support the detection of breast cancer at the earliest, most treatable, stage.